Associated Papers
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
40734624 (PubMed )
Supplement: CAS-116-2868-s002.xlsx › Table_S6
The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing.
Liao J et al.
Jto Clinical and Research Reports, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
40200811 (PubMed )
Supplement: cbm-22-237-s001.pdf
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
Bai Q et al.
Therapeutic Advances in Medical Oncology, 2024
Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer.
Cotto KC et al.
Nature Communications, 2023
36949070 (PubMed )
Supplement: 41467_2023_37266_MOESM8_ESM.xlsx › supplemental_file_6
Optimized Detection of Unknown MET Exon 14 Skipping Mutations in Routine Testing for Patients With Non-Small-Cell Lung Cancer.
Sun R et al.
Jco Precision Oncology, 2023
Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma.
Liu X et al.
Frontiers in Oncology, 2023
38023198 (PubMed )
Supplement: Table_1.xlsx › Table_S2
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
Adib E et al.
Genome Medicine, 2022
35428358 (PubMed )
Supplement: 13073_2022_1041_MOESM2_ESM.xlsx › S4_MET_Druggable
Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration.
Cytryn S et al.
Lung Cancer (amsterdam, Netherlands), 2021
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
Rose Brannon A et al.
Nature Communications, 2021
34145282 (PubMed )
Supplement: 41467_2021_24109_MOESM4_ESM.xlsx › Supplementary_Data_1
Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations.
Kato Y et al.
International Journal of Clinical Oncology, 2021
Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib.
Cheng T et al.
Journal of Cancer, 2021
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA et al.
Lung Cancer (amsterdam, Netherlands), 2020
Select a paper to view details